Skip to main content
SpringerLink
Log in

Heparin-Induced Thrombocytopenia: Diagnosis and Management

  • Chapter
  • First Online:
Nonmalignant Hematology

  • 1626 Accesses

Abstract

Heparin-induced thrombocytopenia (HIT) is a prothrombotic adverse reaction to heparin mediated by platelet-activating antibodies that target multimolecular complexes of platelet factor 4 (PF4) and heparin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95–6.

    CAS  PubMed  Google Scholar 

  • Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–17.

    Article  CAS  PubMed  Google Scholar 

  • Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis. 2005;19:183–8.

    Article  CAS  PubMed  Google Scholar 

  • Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952–9.

    Article  CAS  PubMed  Google Scholar 

  • Chong BH, Gallus AS, Cade JF, Magnani H, Manuharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN, Australian Hit Study Group. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001;86:1170–5.

    CAS  PubMed  Google Scholar 

  • Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119:2209–18.

    Article  CAS  PubMed  Google Scholar 

  • Cuker A, Ortel TL. ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT? Hematol Am Soc Hematol Educ Program. 2009;2009:250–2.

    Google Scholar 

  • Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8:2642–50.

    Article  CAS  PubMed  Google Scholar 

  • Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120:4160–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy 2nd HL, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533–9.

    Article  CAS  PubMed  Google Scholar 

  • Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;94:132–5.

    CAS  PubMed  Google Scholar 

  • Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5:1666–73.

    Article  CAS  PubMed  Google Scholar 

  • Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008;48:2128–32.

    Article  PubMed  Google Scholar 

  • Joseph L, Casanegra A, Dhariwal M, Smith MA, Raju MG, Militello MA, Gomes MP, Gornik HL, Bartholomew JR. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia. J Thromb Haemost. 2014;12:1044–53.

    Article  CAS  PubMed  Google Scholar 

  • Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langer A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125:924–9.

    Article  CAS  PubMed  Google Scholar 

  • Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risk in heparin-induced thrombocytopenia. Chest. 2006;129:1407–16.

    Article  CAS  PubMed  Google Scholar 

  • Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of ACCP Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e495S–530.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, Crowther MA. Design of the rivaroxaban for heparin-induced thrombocytopenia study. J Thromb Thrombolysis. 2014;38:485–92.

    Article  CAS  PubMed  Google Scholar 

  • Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759–65.

    Article  CAS  PubMed  Google Scholar 

  • Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343:515.

    Article  CAS  PubMed  Google Scholar 

  • Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999;111:700–6.

    Article  CAS  PubMed  Google Scholar 

  • Refaai MA, Chuang C, Menegus M, Blumberg N, Francis CW. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2010;8:1419–21.

    Article  CAS  PubMed  Google Scholar 

  • Sheth SB, Dicicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost. 2001;85:435–40.

    CAS  PubMed  Google Scholar 

  • Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy 2nd HL, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006;131:686–92.

    Article  CAS  PubMed  Google Scholar 

  • Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost. 1999;82:1199–200.

    CAS  PubMed  Google Scholar 

  • Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol. 2010;3:567–81.

    Article  CAS  PubMed  Google Scholar 

  • Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–7.

    Article  CAS  PubMed  Google Scholar 

  • Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286–92.

    Article  CAS  PubMed  Google Scholar 

  • Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804–12.

    Article  CAS  PubMed  Google Scholar 

  • Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127:1857–61.

    Article  PubMed  Google Scholar 

  • Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6:1304–12.

    Article  CAS  PubMed  Google Scholar 

  • Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009;113:4963–9.

    Article  CAS  PubMed  Google Scholar 

  • Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood. 2015;125:195–8.

    Article  CAS  PubMed  Google Scholar 

  • Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159:528–40.

    PubMed  Google Scholar 

  • Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2:2133–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Lova Sun & Adam Cuker

  2. Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Adam Cuker

  3. Department of Medicine and Department of Pathology & Laboratory Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Adam Cuker

Authors
  1. Lova Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adam Cuker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam Cuker .

Editor information

Editors and Affiliations

  1. Cancer Treatment Centers of America, Department of Hematology and Bone Marrow Transplantion, Zion, Illinois, USA

    Syed A. Abutalib

  2. Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Jean M. Connors

  3. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    Margaret V. Ragni

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sun, L., Cuker, A. (2016). Heparin-Induced Thrombocytopenia: Diagnosis and Management. In: Abutalib, S., Connors, J., Ragni, M. (eds) Nonmalignant Hematology. Springer, Cham. https://doi.org/10.1007/978-3-319-30352-9_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30352-9_45

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30350-5

  • Online ISBN: 978-3-319-30352-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation